NELA continues to advance in the development of its implant, achieving promising results in a pilot test in sheep, aiming to obtain preliminary histological data. The results showed a significant improvement in the host’s tolerability to the implant, evidenced due to a decrease in the peri-implant granulocytic reaction (reduced fibrosis + reduced neovascularization + reduced inflammatory reaction).

These advances will be exhibited by our CEO José Expósito-Ollero on November 8th 2021 at the “INTERNATIONAL CONFERENCE ON ARTHROPLASTY AND ORTHOPEDIC SURGERY – Technological Advancements in Arthroplasty and Orthopedic Surgery”, held in Vienna, Austria.

You can see the full scientific program here.